Hernandez-Breijo B, et al. - In this prospective observational study, 180 candidates were assessed by investigators to analyze the impact of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and their clinical acknowledgment to tumor necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) cases. About 44% of individuals were given concomitant csDMARDs. An independent relation was noted between the administration of concomitant csDMARDs and serum TNFi drug persistence. They reported a positive contribution of concomitant csDMARDs in obtaining clinical response and remission in overweight/obese people (no association was found for normal-weight subjects).